Cancer vaccine MUC-1 - GlaxoSmithKline/University of Pittsburgh

Drug Profile

Cancer vaccine MUC-1 - GlaxoSmithKline/University of Pittsburgh

Alternative Names: MUC-1 peptide vaccine - GlaxoSmithKline/University of Pittsburgh

Latest Information Update: 20 Nov 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline; University of Pittsburgh
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Pancreatic cancer

Most Recent Events

  • 26 Jan 2007 No development reported - Phase-I for Cancer in USA (Injection)
  • 26 Jan 2007 No development reported - Phase-I for Pancreatic cancer in USA (Injection)
  • 30 Jul 2002 This vaccine is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top